Carregant...
Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
BACKGROUND: A significant minority of asthma patients remain uncontrolled despite the use of inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA). A number of add-on therapies, including monoclonal antibodies (namely omalizumab) and more recently tiotropium bromide have been recommende...
Guardat en:
| Publicat a: | Cost Eff Resour Alloc |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5789632/ https://ncbi.nlm.nih.gov/pubmed/29422778 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12962-018-0089-8 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|